{"id":69108,"date":"2026-06-30T15:11:37","date_gmt":"2026-06-30T07:11:37","guid":{"rendered":"https:\/\/flcube.com\/?p=69108"},"modified":"2026-06-30T15:11:38","modified_gmt":"2026-06-30T07:11:38","slug":"eli-lilly-partners-with-innovent-biologics-on-verzenio-cdk4-6-inhibitor-chinese-biotech-secures-exclusive-commercialization-rights-in-mainland-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69108","title":{"rendered":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) and <strong>Innovent Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced a strategic collaboration granting <strong>Innovent exclusive commercialization rights<\/strong> for <strong>Verzenio (abemaciclib tablets)<\/strong>, Lilly&#8217;s <strong>CDK4\/6 inhibitor<\/strong>, in <strong>Mainland China<\/strong>, while Lilly retains manufacturing, supply, and development responsibilities as the <strong>Marketing Authorization Holder (MAH)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-collaboration-structure\" class=\"wp-block-heading\">Collaboration Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Eli Lilly Responsibility<\/th><th>Innovent Biologics Responsibility<\/th><\/tr><\/thead><tbody><tr><td><strong>Commercialization<\/strong><\/td><td>None (exclusive rights transferred)<\/td><td>Exclusive marketing and sales in Mainland China<\/td><\/tr><tr><td><strong>Manufacturing &amp; Supply<\/strong><\/td><td>Full responsibility<\/td><td>None<\/td><\/tr><tr><td><strong>Product Development<\/strong><\/td><td>Ongoing clinical development<\/td><td>None<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>MAH (Marketing Authorization Holder)<\/td><td>Commercial partner<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (excluding China commercial rights)<\/td><td>Mainland China exclusive<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-verzenio-abemaciclib\" class=\"wp-block-heading\">Product Profile: Verzenio (Abemaciclib)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: CDK4\/6 (cyclin-dependent kinase 4\/6) inhibitor<\/li>\n\n\n\n<li><strong>Indications in China<\/strong>: Multiple approvals covering both early and advanced breast cancer<\/li>\n\n\n\n<li><strong>Reimbursement Status<\/strong>: Included in China&#8217;s National Reimbursement Drug List (NRDL) since 2021<\/li>\n\n\n\n<li><strong>NRDL Renewal<\/strong>: Successfully renewed in 2025 with expanded coverage<\/li>\n\n\n\n<li><strong>Development Origin<\/strong>: Developed by Eli Lilly<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Verzenio represents a cornerstone therapy in breast cancer treatment, targeting the cell cycle machinery that drives tumor proliferation. The drug&#8217;s dual approval for both early-stage (adjuvant) and advanced (metastatic) breast cancer positions it as a comprehensive solution across the disease continuum.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-rationale\" class=\"wp-block-heading\">Market Context &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Driver<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>China Breast Cancer Burden<\/strong><\/td><td>~420,000 new cases annually; leading cause of cancer death among women<\/td><\/tr><tr><td><strong>CDK4\/6 Market Growth<\/strong><\/td><td>China CDK4\/6 inhibitor market projected to reach $1.2 billion by 2028<\/td><\/tr><tr><td><strong>Reimbursement Advantage<\/strong><\/td><td>NRDL inclusion since 2021 ensures broad patient access and affordability<\/td><\/tr><tr><td><strong>Innovent&#8217;s Commercial Strength<\/strong><\/td><td>Established oncology sales force with strong hospital penetration<\/td><\/tr><tr><td><strong>Lilly&#8217;s Strategic Focus<\/strong><\/td><td>Leverages local partner expertise while maintaining product quality control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">China represents one of the world&#8217;s largest and fastest-growing breast cancer markets, with significant unmet need for targeted therapies. The NRDL inclusion has been critical for Verzenio&#8217;s market penetration, reducing patient out-of-pocket costs by up to 80% and enabling broader adoption across tier 1-3 hospitals.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-commercial-outlook\" class=\"wp-block-heading\">Competitive Landscape &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Chinese CDK4\/6 inhibitor market currently includes multiple players:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer&#8217;s Ibrance (palbociclib)<\/strong> \u2013 First-to-market advantage<\/li>\n\n\n\n<li><strong>Novartis&#8217; Kisqali (ribociclib)<\/strong> \u2013 Strong clinical data package<\/li>\n\n\n\n<li><strong>Lilly&#8217;s Verzenio (abemaciclib)<\/strong> \u2013 Unique dosing flexibility and early-stage indication<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Innovent&#8217;s established commercial infrastructure, particularly its oncology-focused sales team and relationships with key opinion leaders, positions Verzenio for accelerated market share gains. The company&#8217;s experience commercializing other premium oncology products provides a proven playbook for maximizing NRDL-reimbursed drug adoption.<\/p>\n\n\n\n<h2 id=\"h-financial-implications\" class=\"wp-block-heading\">Financial Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While specific financial terms were not disclosed, typical China commercialization partnerships include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront payments<\/strong> to the innovator (Lilly)<\/li>\n\n\n\n<li><strong>Sales-based royalties<\/strong> or profit-sharing arrangements<\/li>\n\n\n\n<li><strong>Milestone payments<\/strong> tied to market share or revenue targets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The arrangement allows Lilly to maintain consistent global product quality while benefiting from Innovent&#8217;s local market expertise and commercial execution capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the collaboration, market expectations, and commercial performance of Verzenio in China. Actual results may differ due to risks including competitive dynamics, reimbursement policy changes, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69109,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,199,910,198,911],"class_list":["post-69108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-eli-lilly","tag-hkg-1801","tag-innovent-biologics","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly&#039;s CDK4\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69108\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly&#039;s CDK4\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69108\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T07:11:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-30T07:11:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\\\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China\",\"datePublished\":\"2026-06-30T07:11:37+00:00\",\"dateModified\":\"2026-06-30T07:11:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108\"},\"wordCount\":491,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/3004.webp\",\"keywords\":[\"Cancer\",\"Eli Lilly\",\"HKG: 1801\",\"Innovent Biologics\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69108#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69108\",\"name\":\"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\\\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/3004.webp\",\"datePublished\":\"2026-06-30T07:11:37+00:00\",\"dateModified\":\"2026-06-30T07:11:38+00:00\",\"description\":\"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly's CDK4\\\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69108\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/3004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/3004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\\\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69108#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\\\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly's CDK4\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69108","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China","og_description":"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly's CDK4\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).","og_url":"https:\/\/flcube.com\/?p=69108","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T07:11:37+00:00","article_modified_time":"2026-06-30T07:11:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69108#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69108"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China","datePublished":"2026-06-30T07:11:37+00:00","dateModified":"2026-06-30T07:11:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69108"},"wordCount":491,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69108#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","keywords":["Cancer","Eli Lilly","HKG: 1801","Innovent Biologics","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69108#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69108","url":"https:\/\/flcube.com\/?p=69108","name":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69108#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69108#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","datePublished":"2026-06-30T07:11:37+00:00","dateModified":"2026-06-30T07:11:38+00:00","description":"Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent exclusive commercialization rights for Verzenio (abemaciclib tablets), Lilly's CDK4\/6 inhibitor, in Mainland China, while Lilly retains manufacturing, supply, and development responsibilities as the Marketing Authorization Holder (MAH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69108#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69108"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69108#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","width":1080,"height":608,"caption":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69108#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Partners with Innovent Biologics on Verzenio CDK4\/6 Inhibitor \u2013 Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/3004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69108"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69108\/revisions"}],"predecessor-version":[{"id":69110,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69108\/revisions\/69110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69109"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}